Busch Off to Shire, Moeller Up In Bayer R&D Consolidation; Xofigo Trial Turns Up Safety Issue
Executive Summary
Bayer is combining its research and development organization in one unit. Discovery head Andreas Busch is leaving to join Shire while development head Joerg Moeller takes overall control. Meanwhile, Xofigo was linked to more fractures and deaths than the control arm in a prostate cancer trial.
You may also be interested in...
Appointments: EMD Serono, Cellectis, Shire, Bayer, Biogen, Horizon, Alligator, Faron, Ironwood, Vectura
The latest biopharma industry appointments include R&D leadership appointments at Shire, Bayer, Alligator and Horizon Pharma, new chief medical officers for Shire and Alligator, and a new chief commercial officer for Faron Pharmaceuticals. Meanwhile, Biogen has brought in a new chief information officer.
Shire Tempts Busch From Bayer As It Eyes Top Spot In Rare Diseases
The appointment of Andreas Busch as its new head of R&D represents a boost for Shire which has 17 programs in late-stage development, headed by the potential HAE blockbuster SHP643.
Loxo’s Tissue-Agnostic Approach Brings $400m Upfront From Bayer
The German pharma signs collaboration to develop and commercialize larotrectinib and a follow-on, under a structure that enables Loxo to co-promote in the US and build commercial infrastructure.